Viking Therapeutics (VKTX) Investor Outlook: No Revenue, Obesity Drug in Phase 2

Viking Therapeutics Inc. (NASDAQ: VKTX) is a small‑cap biotechnology company that has yet to generate any revenue or e...

Read story →